1. A pharmaceutical composition suitable for injection containing an effective amount of anakinra and mannitol in an amount of 5 to 50 mg / ml, wherein said pharmaceutical composition does not contain citrate. The pharmaceutical composition according to claim 1, which is adapted for subcutaneous injection of anakinra. A pharmaceutical composition according to claim 1 or 2, wherein said effective amount of anakinra is from 20 to 200 mg / ml. A pharmaceutical composition according to claim 1 or 2, further comprising a chelating agent. 5. The pharmaceutical composition of claim 4, wherein said chelating agent is EDTA in an amount of 0.05 to 1 mM. A pharmaceutical composition according to claim 1 or 2, further comprising an emulsifier. The pharmaceutical composition of claim 6, wherein said emulsifier is a non-ionic surfactant Polysorbate 80 in an amount of from 0.01 to 1% .8. The pharmaceutical composition according to claim 7, containing 150 mg / ml anakinra, 0.5 mm EDTU and 0.1% Polysorbate 80.9. A pharmaceutical composition according to claim 1 or 2, further comprising a tonicity regulating agent in an amount sufficient to ensure isotonicity of the composition. The pharmaceutical composition of claim 9, wherein said tonicity control substance is NaCl in an amount of from 120 to 240 mM. The pharmaceutical composition of claim 9, wherein said tonicity regulating agent is a mixture of NaCl and a second tonicity regulating agent selected from the group consisting of monosaccharides, disaccharides and sugar alcohols. A pharmaceutical composition according to claim 1 or 2, not containing an additional buffering agent. The pharmaceutical composition according to claim 1 or 2, with1. Фармацевтическая композиция, приемлемая для инъекции, содержащая эффективное количество анакинры и маннит в количестве от 5 до 50 мг/мл, где указанная фармацевтическая композиция не содержит цитрата.2. Фармацевтическая композиция по п. 1, которая приспособлена для подкожной инъекции анакинры.3.
